These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 36185176)

  • 1. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
    Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
    Front Oncol; 2022; 12():976224. PubMed ID: 36185176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
    Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
    BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liang Y; Xu H; Liu F; Li L; Lin C; Zhang Y; Wang N; Wang L
    Front Oncol; 2024; 14():1281645. PubMed ID: 38887231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis.
    Fan Y; Xie W; Huang H; Wang Y; Li G; Geng Y; Hao Y; Zhang Z
    Front Oncol; 2021; 11():633032. PubMed ID: 33912454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between immune-related adverse events and prognosis in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ma S; Nie H; Wei C; Jin C; Wang L
    Front Oncol; 2024; 14():1402017. PubMed ID: 38779082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.
    Tan S; Zheng Q; Zhang W; Zhou M; Xia C; Feng W
    Front Immunol; 2024; 15():1408700. PubMed ID: 39050856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Li N; Zheng X; Gan J; Zhuo T; Li X; Yang C; Wu Y; Qin S
    Chin Med J (Engl); 2023 Nov; 136(21):2562-2572. PubMed ID: 37925595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
    Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
    BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis.
    Wang D; Chen C; Gu Y; Lu W; Zhan P; Liu H; Lv T; Song Y; Zhang F
    Front Oncol; 2021; 11():631949. PubMed ID: 33732650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
    Huang Y; Ma W; Wu D; Lyu M; Zheng Q; Wang T; Zhou J; Liu C
    Transl Lung Cancer Res; 2024 Jul; 13(7):1559-1584. PubMed ID: 39118883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis.
    Lin L; Liu Y; Chen C; Wei A; Li W
    Front Pharmacol; 2023; 14():1190001. PubMed ID: 37284302
    [No Abstract]   [Full Text] [Related]  

  • 14. The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis.
    Xu H; Xu X; Ge W; Lei J; Cao D
    Ther Adv Med Oncol; 2020; 12():1758835920980546. PubMed ID: 33425028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
    Liang X; Chen X; Li H; Li Y
    Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
    Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
    Front Oncol; 2022; 12():753234. PubMed ID: 35280736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors.
    Bai R; Li L; Chen X; Chen N; Song W; Zhang Y; Lv Z; Han F; Zhao Y; Li W; Cui J
    J Oncol; 2021; 2021():9935076. PubMed ID: 34335763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Li F; Zhai S; Lv Z; Yuan L; Wang S; Jin D; Yi H; Fu L; Mao Y
    Front Oncol; 2022; 12():968517. PubMed ID: 36439448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors.
    Zhang YC; Zhu TC; Nie RC; Lu LH; Xiang ZC; Xie D; Luo RZ; Cai MY
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.